These findings uncover the role of MORC2 in DNA damage-induced G2 checkpoint via NAT10-mediated acetylation and suggest a potential therapeutic strategy to enhance the sensitivity of breast cancer cells to DNA-damaging treatments by targeting NAT10.49 Here, MORC2 is linked to breast carcinoma.